SALT LAKE CITY, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President of Myriad Genetic Laboratories, Inc. is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 2:55 p.m. Eastern on September 10, 2013 in New York City.
The presentation will be available to interested parties through a live audio webcast accessible through a link on the investor relations section of Myriad's Web site at www.myriad.com .
About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com . MYGN-G
CONTACT: Media Contact: Ron Rogers (801) 584-3065 firstname.lastname@example.org Investor Contact: Scott Gleason (801) 584-1143 email@example.com